半固体投与剤の世界市場2023年:軟膏、ペースト、絆創膏、ジェル

■ 英語タイトル:Global Semi-solid Dosage Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート(データ管理コード:QYR23MA6923)■ 発行会社/調査会社:QYResearch
■ 商品コード:QYR23MA6923
■ 発行日:2023年3月
■ 調査対象地域:グローバル
■ 産業分野:医薬品
■ ページ数:114
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後2-3営業日)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,900 ⇒換算¥440,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD4,350 ⇒換算¥661,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,800 ⇒換算¥881,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[半固体投与剤の世界市場2023年:軟膏、ペースト、絆創膏、ジェル]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

本調査資料は半固体投与剤のグローバル市場について調査・分析し、世界の半固体投与剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析(軟膏、ペースト、絆創膏、ジェル)、用途別セグメント分析(皮膚、鼻腔、膣腔、直腸腔、その他)、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Johnson & Johnson、Merck & Co、Bayer AG、Hisamitsu Pharmaceutical、Glenmark Pharmaceuticals、Cipla Ltd、Nestle SA、Novartis AG、GlaxoSmithKline plc、Bausch Health Companies、Allergan、Biofrontera、Crown Laboratories、Akorn、Ingenus Pharmaceuticals、Sun Pharmaceuticals、Crescita Therapeutics、Mylan N.V.、Encore Dermatology、LEO Pharma、Almirall, S.A、Aclaris Therapeutics、Taro Pharmaceutical Industries、Teligent Pharma、Perrigo Pharmaなどが含まれています。半固体投与剤のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。新型コロナとロシア・ウクライナ戦争の影響は、半固体投与剤市場規模を算出する際に考慮しました。

・半固体投与剤市場の概要
- 製品の定義
- 半固体投与剤の種類別セグメント
- 世界の半固体投与剤市場規模:タイプ別分析(軟膏、ペースト、絆創膏、ジェル)
- 半固体投与剤の用途別セグメント
- 世界の半固体投与剤市場規模:用途別分析(皮膚、鼻腔、膣腔、直腸腔、その他)
- 世界の半固体投与剤市場規模予測(2018年-2029年)
- 半固体投与剤の平均価格推移(2018年-2029年)
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 半固体投与剤市場の競争状況およびトレンド

・半固体投与剤の地域別市場規模
- 北米の半固体投与剤市場規模(2018年-2029年)
- 米国の半固体投与剤市場規模(2018年-2029年)
- ヨーロッパの半固体投与剤市場規模(2018年-2029年)
- アジア太平洋の半固体投与剤市場規模(2018年-2029年)
- 中国の半固体投与剤市場規模(2018年-2029年)
- 日本の半固体投与剤市場規模(2018年-2029年)
- 韓国の半固体投与剤市場規模(2018年-2029年)
- インドの半固体投与剤市場規模(2018年-2029年)
- オーストラリアの半固体投与剤市場規模(2018年-2029年)
- 中南米の半固体投与剤市場規模(2018年-2029年)
- 中東・アフリカの半固体投与剤市場規模(2018年-2029年)

・種類別セグメント:軟膏、ペースト、絆創膏、ジェル
- 世界の半固体投与剤のタイプ別販売量(2018年-2023年)
- 世界の半固体投与剤のタイプ別売上(2018年-2023年)
- 世界の半固体投与剤のタイプ別価格

・用途別セグメント:皮膚、鼻腔、膣腔、直腸腔、その他
- 世界の半固体投与剤の用途別販売量(2018年-2023年)
- 世界の半固体投与剤の用途別売上(2018年-2023年)
- 世界の半固体投与剤の用途別価格

・主要企業のプロファイル:企業情報、事業概要、売上、製品ポートフォリオ、動向
Johnson & Johnson、Merck & Co、Bayer AG、Hisamitsu Pharmaceutical、Glenmark Pharmaceuticals、Cipla Ltd、Nestle SA、Novartis AG、GlaxoSmithKline plc、Bausch Health Companies、Allergan、Biofrontera、Crown Laboratories、Akorn、Ingenus Pharmaceuticals、Sun Pharmaceuticals、Crescita Therapeutics、Mylan N.V.、Encore Dermatology、LEO Pharma、Almirall, S.A、Aclaris Therapeutics、Taro Pharmaceutical Industries、Teligent Pharma、Perrigo Pharma

・産業チェーンと販売チャネルの分析
- 半固体投与剤産業チェーン分析
- 半固体投与剤の主要原材料
- 半固体投与剤の販売チャネル
- 半固体投与剤のディストリビューター
- 半固体投与剤の主要顧客

・半固体投与剤市場ダイナミクス
- 半固体投与剤の業界動向
- 半固体投与剤市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Highlights
The global Semi-solid Dosage market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Semi-solid Dosage is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Semi-solid Dosage is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Semi-solid Dosage include Johnson & Johnson, Merck & Co, Bayer AG, Hisamitsu Pharmaceutical, Glenmark Pharmaceuticals, Cipla Ltd, Nestle SA, Novartis AG and GlaxoSmithKline plc, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Semi-solid Dosage, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Semi-solid Dosage.
The Semi-solid Dosage market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Semi-solid Dosage market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Semi-solid Dosage manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Johnson & Johnson
Merck & Co
Bayer AG
Hisamitsu Pharmaceutical
Glenmark Pharmaceuticals
Cipla Ltd
Nestle SA
Novartis AG
GlaxoSmithKline plc
Bausch Health Companies
Allergan
Biofrontera
Crown Laboratories
Akorn
Ingenus Pharmaceuticals
Sun Pharmaceuticals
Crescita Therapeutics
Mylan N.V.
Encore Dermatology
LEO Pharma
Almirall, S.A
Aclaris Therapeutics
Taro Pharmaceutical Industries
Teligent Pharma
Perrigo Pharma
Segment by Type
Ointment
Paste
Plaster
Gel
Segment by Application
Skin
Nasal Cavity
Vaginal Cavity
Rectal Cavity
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Semi-solid Dosage manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Semi-solid Dosage in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

1 Semi-solid Dosage Market Overview
1.1 Product Overview and Scope of Semi-solid Dosage
1.2 Semi-solid Dosage Segment by Type
1.2.1 Global Semi-solid Dosage Market Value Comparison by Type (2023-2029)
1.2.2 Ointment
1.2.3 Paste
1.2.4 Plaster
1.2.5 Gel
1.3 Semi-solid Dosage Segment by Application
1.3.1 Global Semi-solid Dosage Market Value by Application: (2023-2029)
1.3.2 Skin
1.3.3 Nasal Cavity
1.3.4 Vaginal Cavity
1.3.5 Rectal Cavity
1.3.6 Other
1.4 Global Semi-solid Dosage Market Size Estimates and Forecasts
1.4.1 Global Semi-solid Dosage Revenue 2018-2029
1.4.2 Global Semi-solid Dosage Sales 2018-2029
1.4.3 Global Semi-solid Dosage Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Semi-solid Dosage Market Competition by Manufacturers
2.1 Global Semi-solid Dosage Sales Market Share by Manufacturers (2018-2023)
2.2 Global Semi-solid Dosage Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Semi-solid Dosage Average Price by Manufacturers (2018-2023)
2.4 Global Semi-solid Dosage Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Semi-solid Dosage, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Semi-solid Dosage, Product Type & Application
2.7 Semi-solid Dosage Market Competitive Situation and Trends
2.7.1 Semi-solid Dosage Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Semi-solid Dosage Players Market Share by Revenue
2.7.3 Global Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Semi-solid Dosage Retrospective Market Scenario by Region
3.1 Global Semi-solid Dosage Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Semi-solid Dosage Global Semi-solid Dosage Sales by Region: 2018-2029
3.2.1 Global Semi-solid Dosage Sales by Region: 2018-2023
3.2.2 Global Semi-solid Dosage Sales by Region: 2024-2029
3.3 Global Semi-solid Dosage Global Semi-solid Dosage Revenue by Region: 2018-2029
3.3.1 Global Semi-solid Dosage Revenue by Region: 2018-2023
3.3.2 Global Semi-solid Dosage Revenue by Region: 2024-2029
3.4 North America Semi-solid Dosage Market Facts & Figures by Country
3.4.1 North America Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Semi-solid Dosage Sales by Country (2018-2029)
3.4.3 North America Semi-solid Dosage Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Semi-solid Dosage Market Facts & Figures by Country
3.5.1 Europe Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Semi-solid Dosage Sales by Country (2018-2029)
3.5.3 Europe Semi-solid Dosage Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Semi-solid Dosage Market Facts & Figures by Country
3.6.1 Asia Pacific Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Semi-solid Dosage Sales by Country (2018-2029)
3.6.3 Asia Pacific Semi-solid Dosage Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Semi-solid Dosage Market Facts & Figures by Country
3.7.1 Latin America Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Semi-solid Dosage Sales by Country (2018-2029)
3.7.3 Latin America Semi-solid Dosage Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Semi-solid Dosage Market Facts & Figures by Country
3.8.1 Middle East and Africa Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Semi-solid Dosage Sales by Country (2018-2029)
3.8.3 Middle East and Africa Semi-solid Dosage Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Semi-solid Dosage Sales by Type (2018-2029)
4.1.1 Global Semi-solid Dosage Sales by Type (2018-2023)
4.1.2 Global Semi-solid Dosage Sales by Type (2024-2029)
4.1.3 Global Semi-solid Dosage Sales Market Share by Type (2018-2029)
4.2 Global Semi-solid Dosage Revenue by Type (2018-2029)
4.2.1 Global Semi-solid Dosage Revenue by Type (2018-2023)
4.2.2 Global Semi-solid Dosage Revenue by Type (2024-2029)
4.2.3 Global Semi-solid Dosage Revenue Market Share by Type (2018-2029)
4.3 Global Semi-solid Dosage Price by Type (2018-2029)
5 Segment by Application
5.1 Global Semi-solid Dosage Sales by Application (2018-2029)
5.1.1 Global Semi-solid Dosage Sales by Application (2018-2023)
5.1.2 Global Semi-solid Dosage Sales by Application (2024-2029)
5.1.3 Global Semi-solid Dosage Sales Market Share by Application (2018-2029)
5.2 Global Semi-solid Dosage Revenue by Application (2018-2029)
5.2.1 Global Semi-solid Dosage Revenue by Application (2018-2023)
5.2.2 Global Semi-solid Dosage Revenue by Application (2024-2029)
5.2.3 Global Semi-solid Dosage Revenue Market Share by Application (2018-2029)
5.3 Global Semi-solid Dosage Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Johnson & Johnson Semi-solid Dosage Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Corporation Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co Semi-solid Dosage Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Bayer AG
6.3.1 Bayer AG Corporation Information
6.3.2 Bayer AG Description and Business Overview
6.3.3 Bayer AG Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bayer AG Semi-solid Dosage Product Portfolio
6.3.5 Bayer AG Recent Developments/Updates
6.4 Hisamitsu Pharmaceutical
6.4.1 Hisamitsu Pharmaceutical Corporation Information
6.4.2 Hisamitsu Pharmaceutical Description and Business Overview
6.4.3 Hisamitsu Pharmaceutical Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hisamitsu Pharmaceutical Semi-solid Dosage Product Portfolio
6.4.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.5 Glenmark Pharmaceuticals
6.5.1 Glenmark Pharmaceuticals Corporation Information
6.5.2 Glenmark Pharmaceuticals Description and Business Overview
6.5.3 Glenmark Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Glenmark Pharmaceuticals Semi-solid Dosage Product Portfolio
6.5.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.6 Cipla Ltd
6.6.1 Cipla Ltd Corporation Information
6.6.2 Cipla Ltd Description and Business Overview
6.6.3 Cipla Ltd Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Cipla Ltd Semi-solid Dosage Product Portfolio
6.6.5 Cipla Ltd Recent Developments/Updates
6.7 Nestle SA
6.6.1 Nestle SA Corporation Information
6.6.2 Nestle SA Description and Business Overview
6.6.3 Nestle SA Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Nestle SA Semi-solid Dosage Product Portfolio
6.7.5 Nestle SA Recent Developments/Updates
6.8 Novartis AG
6.8.1 Novartis AG Corporation Information
6.8.2 Novartis AG Description and Business Overview
6.8.3 Novartis AG Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Novartis AG Semi-solid Dosage Product Portfolio
6.8.5 Novartis AG Recent Developments/Updates
6.9 GlaxoSmithKline plc
6.9.1 GlaxoSmithKline plc Corporation Information
6.9.2 GlaxoSmithKline plc Description and Business Overview
6.9.3 GlaxoSmithKline plc Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GlaxoSmithKline plc Semi-solid Dosage Product Portfolio
6.9.5 GlaxoSmithKline plc Recent Developments/Updates
6.10 Bausch Health Companies
6.10.1 Bausch Health Companies Corporation Information
6.10.2 Bausch Health Companies Description and Business Overview
6.10.3 Bausch Health Companies Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bausch Health Companies Semi-solid Dosage Product Portfolio
6.10.5 Bausch Health Companies Recent Developments/Updates
6.11 Allergan
6.11.1 Allergan Corporation Information
6.11.2 Allergan Semi-solid Dosage Description and Business Overview
6.11.3 Allergan Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Allergan Semi-solid Dosage Product Portfolio
6.11.5 Allergan Recent Developments/Updates
6.12 Biofrontera
6.12.1 Biofrontera Corporation Information
6.12.2 Biofrontera Semi-solid Dosage Description and Business Overview
6.12.3 Biofrontera Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Biofrontera Semi-solid Dosage Product Portfolio
6.12.5 Biofrontera Recent Developments/Updates
6.13 Crown Laboratories
6.13.1 Crown Laboratories Corporation Information
6.13.2 Crown Laboratories Semi-solid Dosage Description and Business Overview
6.13.3 Crown Laboratories Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Crown Laboratories Semi-solid Dosage Product Portfolio
6.13.5 Crown Laboratories Recent Developments/Updates
6.14 Akorn
6.14.1 Akorn Corporation Information
6.14.2 Akorn Semi-solid Dosage Description and Business Overview
6.14.3 Akorn Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Akorn Semi-solid Dosage Product Portfolio
6.14.5 Akorn Recent Developments/Updates
6.15 Ingenus Pharmaceuticals
6.15.1 Ingenus Pharmaceuticals Corporation Information
6.15.2 Ingenus Pharmaceuticals Semi-solid Dosage Description and Business Overview
6.15.3 Ingenus Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Ingenus Pharmaceuticals Semi-solid Dosage Product Portfolio
6.15.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.16 Sun Pharmaceuticals
6.16.1 Sun Pharmaceuticals Corporation Information
6.16.2 Sun Pharmaceuticals Semi-solid Dosage Description and Business Overview
6.16.3 Sun Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sun Pharmaceuticals Semi-solid Dosage Product Portfolio
6.16.5 Sun Pharmaceuticals Recent Developments/Updates
6.17 Crescita Therapeutics
6.17.1 Crescita Therapeutics Corporation Information
6.17.2 Crescita Therapeutics Semi-solid Dosage Description and Business Overview
6.17.3 Crescita Therapeutics Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Crescita Therapeutics Semi-solid Dosage Product Portfolio
6.17.5 Crescita Therapeutics Recent Developments/Updates
6.18 Mylan N.V.
6.18.1 Mylan N.V. Corporation Information
6.18.2 Mylan N.V. Semi-solid Dosage Description and Business Overview
6.18.3 Mylan N.V. Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Mylan N.V. Semi-solid Dosage Product Portfolio
6.18.5 Mylan N.V. Recent Developments/Updates
6.19 Encore Dermatology
6.19.1 Encore Dermatology Corporation Information
6.19.2 Encore Dermatology Semi-solid Dosage Description and Business Overview
6.19.3 Encore Dermatology Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Encore Dermatology Semi-solid Dosage Product Portfolio
6.19.5 Encore Dermatology Recent Developments/Updates
6.20 LEO Pharma
6.20.1 LEO Pharma Corporation Information
6.20.2 LEO Pharma Semi-solid Dosage Description and Business Overview
6.20.3 LEO Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.20.4 LEO Pharma Semi-solid Dosage Product Portfolio
6.20.5 LEO Pharma Recent Developments/Updates
6.21 Almirall, S.A
6.21.1 Almirall, S.A Corporation Information
6.21.2 Almirall, S.A Semi-solid Dosage Description and Business Overview
6.21.3 Almirall, S.A Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Almirall, S.A Semi-solid Dosage Product Portfolio
6.21.5 Almirall, S.A Recent Developments/Updates
6.22 Aclaris Therapeutics
6.22.1 Aclaris Therapeutics Corporation Information
6.22.2 Aclaris Therapeutics Semi-solid Dosage Description and Business Overview
6.22.3 Aclaris Therapeutics Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Aclaris Therapeutics Semi-solid Dosage Product Portfolio
6.22.5 Aclaris Therapeutics Recent Developments/Updates
6.23 Taro Pharmaceutical Industries
6.23.1 Taro Pharmaceutical Industries Corporation Information
6.23.2 Taro Pharmaceutical Industries Semi-solid Dosage Description and Business Overview
6.23.3 Taro Pharmaceutical Industries Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Taro Pharmaceutical Industries Semi-solid Dosage Product Portfolio
6.23.5 Taro Pharmaceutical Industries Recent Developments/Updates
6.24 Teligent Pharma
6.24.1 Teligent Pharma Corporation Information
6.24.2 Teligent Pharma Semi-solid Dosage Description and Business Overview
6.24.3 Teligent Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Teligent Pharma Semi-solid Dosage Product Portfolio
6.24.5 Teligent Pharma Recent Developments/Updates
6.25 Perrigo Pharma
6.25.1 Perrigo Pharma Corporation Information
6.25.2 Perrigo Pharma Semi-solid Dosage Description and Business Overview
6.25.3 Perrigo Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Perrigo Pharma Semi-solid Dosage Product Portfolio
6.25.5 Perrigo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Semi-solid Dosage Industry Chain Analysis
7.2 Semi-solid Dosage Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Semi-solid Dosage Production Mode & Process
7.4 Semi-solid Dosage Sales and Marketing
7.4.1 Semi-solid Dosage Sales Channels
7.4.2 Semi-solid Dosage Distributors
7.5 Semi-solid Dosage Customers
8 Semi-solid Dosage Market Dynamics
8.1 Semi-solid Dosage Industry Trends
8.2 Semi-solid Dosage Market Drivers
8.3 Semi-solid Dosage Market Challenges
8.4 Semi-solid Dosage Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Semi-solid Dosage Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Semi-solid Dosage Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Semi-solid Dosage Market Competitive Situation by Manufacturers in 2022
Table 4. Global Semi-solid Dosage Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Semi-solid Dosage Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Semi-solid Dosage Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Semi-solid Dosage Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Semi-solid Dosage Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Semi-solid Dosage, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Semi-solid Dosage, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Semi-solid Dosage, Product Type & Application
Table 12. Global Key Manufacturers of Semi-solid Dosage, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Semi-solid Dosage by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Semi-solid Dosage as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Semi-solid Dosage Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Semi-solid Dosage Sales by Region (2018-2023) & (K Units)
Table 18. Global Semi-solid Dosage Sales Market Share by Region (2018-2023)
Table 19. Global Semi-solid Dosage Sales by Region (2024-2029) & (K Units)
Table 20. Global Semi-solid Dosage Sales Market Share by Region (2024-2029)
Table 21. Global Semi-solid Dosage Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Semi-solid Dosage Revenue Market Share by Region (2018-2023)
Table 23. Global Semi-solid Dosage Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Semi-solid Dosage Revenue Market Share by Region (2024-2029)
Table 25. North America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 27. North America Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 28. North America Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 32. Europe Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 33. Europe Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Semi-solid Dosage Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Semi-solid Dosage Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Semi-solid Dosage Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Semi-solid Dosage Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Semi-solid Dosage Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Semi-solid Dosage Sales (K Units) by Type (2018-2023)
Table 51. Global Semi-solid Dosage Sales (K Units) by Type (2024-2029)
Table 52. Global Semi-solid Dosage Sales Market Share by Type (2018-2023)
Table 53. Global Semi-solid Dosage Sales Market Share by Type (2024-2029)
Table 54. Global Semi-solid Dosage Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Semi-solid Dosage Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Semi-solid Dosage Revenue Market Share by Type (2018-2023)
Table 57. Global Semi-solid Dosage Revenue Market Share by Type (2024-2029)
Table 58. Global Semi-solid Dosage Price (USD/Unit) by Type (2018-2023)
Table 59. Global Semi-solid Dosage Price (USD/Unit) by Type (2024-2029)
Table 60. Global Semi-solid Dosage Sales (K Units) by Application (2018-2023)
Table 61. Global Semi-solid Dosage Sales (K Units) by Application (2024-2029)
Table 62. Global Semi-solid Dosage Sales Market Share by Application (2018-2023)
Table 63. Global Semi-solid Dosage Sales Market Share by Application (2024-2029)
Table 64. Global Semi-solid Dosage Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Semi-solid Dosage Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Semi-solid Dosage Revenue Market Share by Application (2018-2023)
Table 67. Global Semi-solid Dosage Revenue Market Share by Application (2024-2029)
Table 68. Global Semi-solid Dosage Price (USD/Unit) by Application (2018-2023)
Table 69. Global Semi-solid Dosage Price (USD/Unit) by Application (2024-2029)
Table 70. Johnson & Johnson Corporation Information
Table 71. Johnson & Johnson Description and Business Overview
Table 72. Johnson & Johnson Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Johnson & Johnson Semi-solid Dosage Product
Table 74. Johnson & Johnson Recent Developments/Updates
Table 75. Merck & Co Corporation Information
Table 76. Merck & Co Description and Business Overview
Table 77. Merck & Co Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Merck & Co Semi-solid Dosage Product
Table 79. Merck & Co Recent Developments/Updates
Table 80. Bayer AG Corporation Information
Table 81. Bayer AG Description and Business Overview
Table 82. Bayer AG Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Bayer AG Semi-solid Dosage Product
Table 84. Bayer AG Recent Developments/Updates
Table 85. Hisamitsu Pharmaceutical Corporation Information
Table 86. Hisamitsu Pharmaceutical Description and Business Overview
Table 87. Hisamitsu Pharmaceutical Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Hisamitsu Pharmaceutical Semi-solid Dosage Product
Table 89. Hisamitsu Pharmaceutical Recent Developments/Updates
Table 90. Glenmark Pharmaceuticals Corporation Information
Table 91. Glenmark Pharmaceuticals Description and Business Overview
Table 92. Glenmark Pharmaceuticals Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Glenmark Pharmaceuticals Semi-solid Dosage Product
Table 94. Glenmark Pharmaceuticals Recent Developments/Updates
Table 95. Cipla Ltd Corporation Information
Table 96. Cipla Ltd Description and Business Overview
Table 97. Cipla Ltd Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. Cipla Ltd Semi-solid Dosage Product
Table 99. Cipla Ltd Recent Developments/Updates
Table 100. Nestle SA Corporation Information
Table 101. Nestle SA Description and Business Overview
Table 102. Nestle SA Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Nestle SA Semi-solid Dosage Product
Table 104. Nestle SA Recent Developments/Updates
Table 105. Novartis AG Corporation Information
Table 106. Novartis AG Description and Business Overview
Table 107. Novartis AG Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Novartis AG Semi-solid Dosage Product
Table 109. Novartis AG Recent Developments/Updates
Table 110. GlaxoSmithKline plc Corporation Information
Table 111. GlaxoSmithKline plc Description and Business Overview
Table 112. GlaxoSmithKline plc Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. GlaxoSmithKline plc Semi-solid Dosage Product
Table 114. GlaxoSmithKline plc Recent Developments/Updates
Table 115. Bausch Health Companies Corporation Information
Table 116. Bausch Health Companies Description and Business Overview
Table 117. Bausch Health Companies Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Bausch Health Companies Semi-solid Dosage Product
Table 119. Bausch Health Companies Recent Developments/Updates
Table 120. Allergan Corporation Information
Table 121. Allergan Description and Business Overview
Table 122. Allergan Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Allergan Semi-solid Dosage Product
Table 124. Allergan Recent Developments/Updates
Table 125. Biofrontera Corporation Information
Table 126. Biofrontera Description and Business Overview
Table 127. Biofrontera Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Biofrontera Semi-solid Dosage Product
Table 129. Biofrontera Recent Developments/Updates
Table 130. Crown Laboratories Corporation Information
Table 131. Crown Laboratories Description and Business Overview
Table 132. Crown Laboratories Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Crown Laboratories Semi-solid Dosage Product
Table 134. Crown Laboratories Recent Developments/Updates
Table 135. Akorn Corporation Information
Table 136. Akorn Description and Business Overview
Table 137. Akorn Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Akorn Semi-solid Dosage Product
Table 139. Akorn Recent Developments/Updates
Table 140. Ingenus Pharmaceuticals Corporation Information
Table 141. Ingenus Pharmaceuticals Description and Business Overview
Table 142. Ingenus Pharmaceuticals Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. Ingenus Pharmaceuticals Semi-solid Dosage Product
Table 144. Ingenus Pharmaceuticals Recent Developments/Updates
Table 145. Sun Pharmaceuticals Corporation Information
Table 146. Sun Pharmaceuticals Description and Business Overview
Table 147. Sun Pharmaceuticals Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 148. Sun Pharmaceuticals Semi-solid Dosage Product
Table 149. Sun Pharmaceuticals Recent Developments/Updates
Table 150. Crescita Therapeutics Corporation Information
Table 151. Crescita Therapeutics Description and Business Overview
Table 152. Crescita Therapeutics Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 153. Crescita Therapeutics Semi-solid Dosage Product
Table 154. Crescita Therapeutics Recent Developments/Updates
Table 155. Mylan N.V. Corporation Information
Table 156. Mylan N.V. Description and Business Overview
Table 157. Mylan N.V. Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 158. Mylan N.V. Semi-solid Dosage Product
Table 159. Mylan N.V. Recent Developments/Updates
Table 160. Encore Dermatology Corporation Information
Table 161. Encore Dermatology Description and Business Overview
Table 162. Encore Dermatology Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 163. Encore Dermatology Semi-solid Dosage Product
Table 164. Encore Dermatology Recent Developments/Updates
Table 165. LEO Pharma Corporation Information
Table 166. LEO Pharma Description and Business Overview
Table 167. LEO Pharma Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 168. LEO Pharma Semi-solid Dosage Product
Table 169. LEO Pharma Recent Developments/Updates
Table 170. Almirall, S.A Corporation Information
Table 171. Almirall, S.A Description and Business Overview
Table 172. Almirall, S.A Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 173. Almirall, S.A Semi-solid Dosage Product
Table 174. Almirall, S.A Recent Developments/Updates
Table 175. Aclaris Therapeutics Corporation Information
Table 176. Aclaris Therapeutics Description and Business Overview
Table 177. Aclaris Therapeutics Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 178. Aclaris Therapeutics Semi-solid Dosage Product
Table 179. Aclaris Therapeutics Recent Developments/Updates
Table 180. Taro Pharmaceutical Industries Corporation Information
Table 181. Taro Pharmaceutical Industries Description and Business Overview
Table 182. Taro Pharmaceutical Industries Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 183. Taro Pharmaceutical Industries Semi-solid Dosage Product
Table 184. Taro Pharmaceutical Industries Recent Developments/Updates
Table 185. Teligent Pharma Corporation Information
Table 186. Teligent Pharma Description and Business Overview
Table 187. Teligent Pharma Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 188. Teligent Pharma Semi-solid Dosage Product
Table 189. Teligent Pharma Recent Developments/Updates
Table 190. Perrigo Pharma Corporation Information
Table 191. Perrigo Pharma Description and Business Overview
Table 192. Perrigo Pharma Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 193. Perrigo Pharma Semi-solid Dosage Product
Table 194. Perrigo Pharma Recent Developments/Updates
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Semi-solid Dosage Distributors List
Table 198. Semi-solid Dosage Customers List
Table 199. Semi-solid Dosage Market Trends
Table 200. Semi-solid Dosage Market Drivers
Table 201. Semi-solid Dosage Market Challenges
Table 202. Semi-solid Dosage Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Semi-solid Dosage
Figure 2. Global Semi-solid Dosage Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Semi-solid Dosage Market Share by Type in 2022 & 2029
Figure 4. Ointment Product Picture
Figure 5. Paste Product Picture
Figure 6. Plaster Product Picture
Figure 7. Gel Product Picture
Figure 8. Global Semi-solid Dosage Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Semi-solid Dosage Market Share by Application in 2022 & 2029
Figure 10. Skin
Figure 11. Nasal Cavity
Figure 12. Vaginal Cavity
Figure 13. Rectal Cavity
Figure 14. Other
Figure 15. Global Semi-solid Dosage Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Semi-solid Dosage Market Size (2018-2029) & (US$ Million)
Figure 17. Global Semi-solid Dosage Sales (2018-2029) & (K Units)
Figure 18. Global Semi-solid Dosage Average Price (USD/Unit) & (2018-2029)
Figure 19. Semi-solid Dosage Report Years Considered
Figure 20. Semi-solid Dosage Sales Share by Manufacturers in 2022
Figure 21. Global Semi-solid Dosage Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Semi-solid Dosage Players: Market Share by Revenue in 2022
Figure 23. Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global Semi-solid Dosage Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 25. North America Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 26. North America Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 27. United States Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 30. Europe Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 31. Germany Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Semi-solid Dosage Sales Market Share by Region (2018-2029)
Figure 37. Asia Pacific Semi-solid Dosage Revenue Market Share by Region (2018-2029)
Figure 38. China Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Japan Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. South Korea Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. India Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Australia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. China Taiwan Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Indonesia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Thailand Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Malaysia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Latin America Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 48. Latin America Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 49. Mexico Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Brazil Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Argentina Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Middle East & Africa Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 53. Middle East & Africa Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 54. Turkey Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. UAE Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Global Sales Market Share of Semi-solid Dosage by Type (2018-2029)
Figure 58. Global Revenue Market Share of Semi-solid Dosage by Type (2018-2029)
Figure 59. Global Semi-solid Dosage Price (USD/Unit) by Type (2018-2029)
Figure 60. Global Sales Market Share of Semi-solid Dosage by Application (2018-2029)
Figure 61. Global Revenue Market Share of Semi-solid Dosage by Application (2018-2029)
Figure 62. Global Semi-solid Dosage Price (USD/Unit) by Application (2018-2029)
Figure 63. Semi-solid Dosage Value Chain
Figure 64. Semi-solid Dosage Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(QYR23MA6923 )"半固体投与剤の世界市場2023年:軟膏、ペースト、絆創膏、ジェル" (英文:Global Semi-solid Dosage Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。